First Horizon Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

First Horizon Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-47	Closed	-$10K	–	1590
2018 Q3	$10K	Hold	47	–	–	﹤0.01%	1122
2018 Q2	$102K	Hold	47	–	–	0.01%	446
2018 Q1	$118K	Hold	47	–	–	0.01%	365
2017 Q4	$84K	Sell	47 -46	-49%	-$66.6K	0.01%	423
2017 Q3	$110K	Hold	93	–	–	0.01%	377
2017 Q2	$69K	Hold	93	–	–	0.01%	430
2017 Q1	$64K	Sell	93 -821	-90%	-$601K	0.01%	472
2016 Q4	$100K	Buy	914 +823	+904%	+$880K	0.01%	404
2016 Q3	$100K	Hold	91	–	–	0.01%	399
2016 Q2	$70K	Hold	91	–	–	0.01%	452
2016 Q1	$64K	Hold	91	–	–	0.01%	493
2015 Q4	$90K	Hold	91	–	–	0.02%	386
2015 Q3	$97K	Buy	+91	New	+$133K	0.02%	403
2013 Q4	–	Sell	-24	Closed	-$69K	–	1427
2013 Q3	$69K	Buy	+24	New	+$119K	0.01%	408

Other funds holding ONCT

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Horizon Advisors's ONCT Position: Q4 2018 in Review

First Horizon Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2018, closing a stake of 47 shares — an estimated $10K sold.

First Horizon Advisors first reported a position in ONCT in Q3 2013 and held it in 14 quarters. The position peaked at $118K in Q1 2018. 43 funds tracked by Wall St. Rank hold ONCT as of Q4 2018.

First Horizon Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
First Horizon Advisors sold 47 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $10K.
First Horizon Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2013 and held it in 14 quarters.
First Horizon Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $118K in Q1 2018.
43 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2018.

Based on First Horizon Advisors's 13F filing for Q4 2018, filed 11 Feb 2019.